Form D · Biotechnology
SISCAPA Assay Technologies, Inc.
Washington, DC · CIK 0001528248
Offering snapshot reported Aug 28, 2025 · SEC filing
- Reported sold
- $2M Offering amount: $2M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Apr 29, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 28, 2025 | Initial | $1,999,940 | No comparison | 1 | SEC filing |
| Apr 11, 2014 | Initial | $1,000,000 | No comparison | 8 | SEC filing |
| Aug 23, 2012 | Initial | $562,000 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-556175
Source: Form D, filed Aug 28, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| N. Leigh Anderson | Director, Executive, Promoter |
| Norman Liegh Anderson | Director, Executive |
| Terry W. Pearson | Director |
| Gus Salem | Director |
| Constance L. Seniff | Director, Executive |
| Guo Liang Yu | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1759 Willard St Nw
Washington, DC, 20009
Washington, DC, 20009